Are you an adult who has just found out you have IDH-Wildtype Glioblastoma? If so, you could join a study to see if a new experimental pill called ropidoxuridine can help make treatment for this type of brain cancer better when used with radiation.

In this study, we want to find out if a new drug called Soquelitinib (also known as CPI-818) can be safely given to people. We are also checking to see if it can help treat a type of cancer called relapsed peripheral T-cell lymphoma (PTCL).

Have you been diagnosed with High-risk Biochemical Recurrence (BCR) of Nonmetastatic Castration-sensitive Prostate Cancer (nmCSPC)? If so, you may be able to take part in a research study evaluating the safety and tolerability of the study drug in adults with High-risk Biochemical Recurrence (BCR) of Nonmetastatic Castratio-sensitive Prostate Cancer (nmCSPC).

Do you have early-stage endometrial cancer? If so, you may be able to take part in a research study looking to find out if there are types of early-stage endometrial cancer that require less treatment than the usual approac

Do you have advanced melanoma that has progressed on treatment? Do you have a tumor longer than 1cm in length? If so, you might be able to take part in a study that compares a study treatment (Vusolimogene Oderparepvec and Nivolumab) with your physician's choice of standard of care treatment. Compensation provided.

Have you been diagnosed with hormone receptor (HR+) and human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer? If so, you may be eligible for a clinical trial investigating the combination of endocrine therapy with alisertib.

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Are you a patient with advanced basal-like pancreatic adenocarcinoma? If so this could the a Trial for you to as this is a Phase I/II trial is to evaluate the safety, efficacy and tolerability of low-dose EGFR inhibitors in combination with bi-weekly gemcitabine/nab-paclitaxel (GnP) in subjects with basal tumors

The purpose of this study is to test the safety and effectiveness of the test drug IMGN151-1001 on your cancer.

Have you been diagnosed with relapsed or refractory light chain amyloidosis? If so, you may be able to take part in a research study looking at the safety and tolerability of giving Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone to patients with relapsed or refractory light chain amyloidosis.